Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360724 · ClinicalTrials.gov registry record · Phase 4
Duloxetine for Chronic Depression: a Double-blind Study
A Phase 4 study of Dysthymic Disorder and Depressive Disorder NOS, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT00360724 is a Phase 4 study of Dysthymic Disorder and Depressive Disorder NOS that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 65 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00360724, a Phase 4 study of Dysthymic Disorder and Depressive Disorder NOS, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major depression. The investigators are testing whether this medicine is also effective for adults with chronic depression (dysthymic disorder or dysthymia). Chronic depression, lasting two or more years, often causes significant suffering and impairment. The investigators study involves a 6 to 10 week double-blind Initial Phase during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the Initial Phase, a 12-week Continuation Phase will begin, during which all subjects can be treated with an FDA-approved antidepressant medication. Eligible subjects may also receive MRI scans, to help the investigators understand how antidepressants work in treating depression.
Conditions Studied
Interventions
- DRUG Duloxetine (Cymbalta)
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360724
The ClinicalTrials.gov registry entry for NCT00360724 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dysthymic Disorder appearing as the primary indexed condition, and to 1 intervention - of which Duloxetine (Cymbalta) is the first listed.
NCT00360724 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00360724 about?
NCT00360724 is a clinical study titled "Duloxetine for Chronic Depression: a Double-blind Study". The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major depression. The investigators are testing whether this medicine is also effectiv...
What is the current status of trial NCT00360724?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2006-08. Estimated completion is 2013-12.
What conditions does trial NCT00360724 study?
This clinical trial studies the following conditions: Dysthymic Disorder, Depressive Disorder NOS.
What interventions are being tested in trial NCT00360724?
The interventions under investigation include: Duloxetine (Cymbalta) (DRUG).
Who is sponsoring clinical trial NCT00360724?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00360724 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dysthymic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.